Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions

Hepatology

Volumn 42, Issue 3, 2005, Pages 657-664

  Yeh, Ta Sen ^a,b   Tseng, Jeng Hwei ^a   Chen, Tse Ching ^a   Liu, Nai Jen ^a   Chiu, Cheng Tang ^a   Jan, Yi Yin ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN 1; MUCIN 2; MUCIN 5AC; PROTEIN P53; TRANSCRIPTION FACTOR CDX2; TREFOIL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER SURVIVAL; CHOLANGIOGRAPHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIVER CARCINOGENESIS; LIVER INTRADUCTAL PAPILLARY TUMOR; LIVER RESECTION; LIVER TUMOR; MAGNETIC RESONANCE CHOLANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOMATOLOGY; WESTERN BLOTTING;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LITHIASIS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 24144436010     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20837     Document Type: Article

References (34)

1. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(Suppl VI):1-9.
2. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, et al. K-ras mutation and p53 protein expression in intrahepatic cholangiocarcinoma: relation to gross tumor morphology. Gastroenterology 1995;109: 1612-1617.
3. Chen MF, Jan YY, Hwang TL, Jeng LB, Yeh TS. Impact of concomitant hepatolithiasis on patients with peripheral cholangiocarcinoma. Dig Dis Sci 2000;45:312-316.
4. Chen MF, Jan YY, Wang CS, Hwang TL, Jeng LB, Chen SC, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer 1993;71:2461-2465.
5. Suh KS, Roh HR, Koh YT, Lee KU, Park YH, Kim SW. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. HEPATOLOGY 2000;31:12-17.
6. Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, et al. Intraductal papillary neoplasia of the liver associated with hepatolithiasis. HEPATOLOGY 2001;34:651-658.
7. Chen MF, Jan YY, Chen TC. Clinical studies of mucin-producing cholangiocellular carcinoma: a study of 22 histopathology-proven cases. Ann Surg 1998;227:63-69.
8. Shibahara H, Tamada S, Goto M, Oda K, Nagino M, Nagasaka T, et al. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:327-338.
9. Shimonishi T, Zen Y, Chen TC, Chen MF, Jan YY, Yeh TS, et al. Increasing expression of gastrointestinal phenotypes and p53 along with histologic progression of intraductal papillary neoplasia of the liver. Hum Pathol 2002;33:503-511.
10. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Letter 2002;176:47-55.
11. Ishikawa A, Sasaki M, Ohira S, Ohta T, Oda K, Nimura Y, et al. Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab Invest 2004;84:629-638.
12. Jan YY, Chen MF, Wang CS. Surgical treatment of hepatolithiasis: long-term results. Surgery 1996;120:509-514.
13. Lim JH, Yoon KH, Kim SH, Kim HY, Lim HK, Song SY, et al. Intraductal papillary mucinous tumor of the bile ducts. Radiographics 2004;24:53-67.
14. Tajima Y, Kuroki T, Fukuda K, Tsuneoka N, Furui J, Kanematsu T. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg 2004;91:99-104.
15. Sasaki A, Aramaki M, Kawano Y, Morii Y, Nakashima K, Yoshida T, et al. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. Br J Surg 1998;85:1206-1209.
16. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and Cdx2 expression during intestinal development. Gastroenterology 2000;119:961-971.
17. Bonhomme C, Duluc I, Martin E, Chawengsaksophak K, Chenard MP, Kedinger M, et al. The Cdx2 homeobox gene has a tumor suppressor function in the distal colon in addition to a homeostatic role during gut development. Gut 2003;52:1465-1471.
18. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36-40.
19. Ren P, Silberg DG, Sirica AE. Expression of an intestine-specific transcription factor (CDX1) in intestine metaplasia and in subsequently developed intestinal type of cholangiocarcinoma in rat liver. Am J Pathol 2000;156:621-627.
20. Eda A, Osawa H, Satoh K, Yanaka I, Kihira K, Ishino Y, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003;38:14-22.
21. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophy Res Comm 2003;300:813-818.
22. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002;295:1726-1729.
23. Longman RJ, Douthwaite J, Sylvester PA, Poulsom R, Corfield AP, Thomas MG, et al. Coordinated localization of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa. Gut 2000;47:792-800.
24. Lefebvre O, Chenard M, Masson R, Linares J, Dierich A, LeMeur M, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996;274:259-262.
25. Sasaki M, Tsuneyama K, Nakanuma Y. Aberrant expression of trefoil factor family 1 in biliary epithelium in hepatolithiasis and cholangiocarcinoma. Lab Invest 2003;83:1403-1413.
26. Takeyama K, Dabbagh K, Lee HM, Agusti C, Lausier JA, Ueki IF, et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999;96:3081-3086.
27. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. Induction of MUC2 and MUC 5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/ Ras/ Raf/ extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002;277:32258-32267.
28. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequence. Nature 1984;307:521-527.
29. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase- 2 regulation in human cholangiocarcinoma and risk conditions. HEPATOLOGY 2002;36:439-450.
30. Sitica AE, Lai GH, Endo K, Zhang Z, Yoon BI. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 2002;22:303-313.
31. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456.
32. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. P53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. HEPATOLOGY 1995;22:774-779.
33. Teh M, Wee A, Raju GC. An immunohistochemical study of protein in gallbladder and extrahepatic bile duct/ampullary carcinoma. Cancer 1994; 74:1542-1545.
34. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, et al. Ki-ras mutations and p53 protein expressions in intraheoatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995;109:1612-1617.